NSAIDsのサブセットは,サイクロオキシゲネーゼの活性から独立して,アミロイド原性Abeta42を低下させる
1Department of Neurosciences, University of California San Diego, La Jolla, California 92093, USA.
Nature
|November 9, 2001
まとめ
非ステロイド性抗炎症薬 (NSAIDs) は,アルツハイマー病の重要な要因であるアミロイドベータ42 (Abeta42) ペプチドのレベルを大幅に低下させます. このAbeta42の減少は,サイクロオキシゲネーゼ抑制とは無関係に発生し,新たな治療経路を示唆しています.
科学分野:
- 神経科学は神経科学である.
- 薬理学 薬理学とは
- 分子生物学は分子生物学である.
背景:
- 流行病学的な研究は,非ステロイド性抗炎症薬 (NSAIDs) がアルツハイマー病の罹患率を減らす可能性があることを示唆しています.
- 提案されたメカニズムは,神経毒性炎症性脳反応を減少させるNSAIDを含むが,これは未証明のままである.
研究 の 目的:
- アミロイドベータペプチドの産生に対するNSAIDの直接的影響を調査する.
- NSAIDが高度にアミロイド誘発性のAbeta42ペプチドを減少させるかどうかを判断し,その背後にあるメカニズムを解明する.
主な方法:
- 培養細胞と変異性β-アミロイド前駆体タンパク質 (APP) のトランスジェニックマウスの様々なNSAID (イブプロフェン,インドメタシン,スリンダック硫化物) による治療.
- アベタ42および他のアベタ同型 (例えば,アベタ ((1-38)) の定量化).
- サイクロオキシゲナーゼ (COX) 活性とノッチ・クリバージュの評価.
主要な成果:
- イブプロフェン,インドメタシン,スリンダック硫化物は,培養細胞でアベタ42の産生を80%まで低下させた.
- このAbeta42の減少は,COX抑制とは無関係に観察されました.
- マウスにイブプロフェンを投与すると,脳のAbeta42レベルが低下しました.
- 同時にアベタ ((1-38) の増加が認められ,微妙なガンマ分泌酵素調節を示唆した.
結論:
- NSAIDは,Abeta42ペプチドのレベルを下げることで,アミロイド病理を直接軽減します.
- アベタ42を低下させる効果は,COX活性とは独立している.
- このメカニズムは,病原性アベタ42種をターゲットにすることで,アルツハイマー病に対する潜在的な治療戦略を提供します.
関連する概念動画
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...


